Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

In the third quarter, Eli Lilly's sales grew by 20% year over year to $11.4 billion, largely thanks to Zepbound and Mounjaro.

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) shares gapped up before the market opened on Friday .The stock had previously closed at $757.54, but opened at $811.35. Eli Lilly and Company ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...